Semaglutide10mg
Semaglutide Canada — 10 mg Lyophilized Vials
GLP-1 Receptor Agonist · 10 mg
Semaglutide is a GLP-1 receptor agonist studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance. In laboratory settings, it is commonly examined for how it influences insulin pathways and body weight–related mechanisms.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
In scientific literature, semaglutide is studied in experimental models examining GLP-1 receptor activation pathways, incretin-related signaling cascades, and downstream endocrine regulatory dynamics under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
Semaglutide is a synthetic, long-acting analogue of glucagon-like peptide-1 (GLP-1) evaluated in research focused on incretin receptor signaling activity. As a compound structurally engineered to interact with GLP-1 receptor systems with extended half-life, it is studied within experimental models examining receptor-driven signaling pathways and metabolic regulatory interaction.
Preclinical and clinical research publications have explored its receptor-binding profile, downstream pathway activation, and GLP-1 receptor signaling dynamics under controlled study conditions.
GLP-1 was identified during investigations into incretin hormone physiology and glucose-dependent insulin secretion. Early research established it as a short-acting endogenous signaling peptide, with subsequent investigations focused on developing structurally modified analogues with improved stability and extended receptor interaction profiles.
Semaglutide emerged from this lineage as a long-acting GLP-1 analogue incorporating structural modifications — including a C-18 fatty acid side chain and backbone substitutions — designed to enhance albumin binding and resistance to dipeptidyl peptidase-4 degradation within experimental systems.
Laboratory investigations into semaglutide have focused on GLP-1 receptor activation models and downstream incretin signaling pathways. Research frameworks evaluate receptor-mediated interaction, endocrine regulatory dynamics, and metabolic signaling mechanisms under controlled in vitro and preclinical conditions.
1 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on receptor, activation or incretin. This heading marks where Semaglutide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on glucose, dependent or endocrine. This heading marks where Semaglutide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on metabolic. This heading marks where Semaglutide is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Lau 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 4 primary papers published between 2015 and 2021 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Semaglutide, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Semaglutide is also referred to as sema.
Approved prescription medicines containing the same active ingredient are sold under the brand names Ozempic, Wegovy, Rybelsus. The material supplied here is not those products and is not interchangeable with them. Those are regulated pharmaceuticals manufactured to a licensed specification and dispensed under medical supervision. This is a research compound, and what is published for it is its measured purity and content per lot.
Widely described online as a weight-loss compound, usually by the brand names of the approved medicines containing it.
Semaglutide is unusual in this catalogue in that it has a large published clinical trial programme — the STEP trials examined it for weight management and reported body-weight endpoints in humans. That research is real and is cited on this page. It was conducted with pharmaceutical-grade material under medical supervision at defined doses, and none of it transfers to material supplied as a research compound, which is what is sold here. Eppix Labs provides no dosing or administration guidance.
Research-grade material described as equivalent to the prescription product.
Research material and an approved pharmaceutical are not equivalent regardless of assay results. An approved product carries a regulated manufacturing process, sterility and endotoxin controls, stability data and a licensed indication. What is published for this material is its measured purity and measured content per lot, plus a heavy-metals, sterility or endotoxin screen on lots chosen at random. A screen that a lot passed is a result about that lot; a control is a validated process that governs every lot, and these are not the same thing. What is claimed here is the narrower one.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Semaglutide is per lot, not per product. The current 10mg lot SEMA-CA-26F-10 returned 99.504% purity, 11.27 mg measured, 112.7% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Semaglutide; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Semaglutide, this lot measured 112.7% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Semaglutide. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Semaglutide in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
Semaglutide is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 30 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 10mg of lyophilized semaglutide. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the lyophilized compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.
PubMedSemaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).
PubMedOnce-weekly semaglutide in adults with overweight or obesity (STEP 1).
PubMedSemaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$144.95CAD
Peptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
